The biological target shapes what a point-of-care test can report. Microbial-antigen assays seek evidence associated with the infectious agent, antibody assays measure a host response, and nucleic-acid systems detect pathogen genetic material. Choosing among these targets matters because the result represents different biological information, so test selection should match the clinical or surveillance question.
These formats support different detection strategies within point-of-care testing. Lateral-flow immunoassays and biosensors can be used to detect microbial antigens or host antibodies, while compact amplification systems are suited to nucleic-acid detection. The distinction helps explain why devices vary in their targets, specimen requirements, and potential clinical or surveillance applications.
Analytical sensitivity, specificity, and specimen quality are central determinants of result reliability. Sensitivity affects whether the test detects the target, specificity affects how selectively it identifies that target, and poor-quality blood, saliva, or swab specimens can undermine performance. Appropriate interpretation must consider these factors rather than treating every rapid result as equally informative.
Selection connects the diagnostic question with both the specimen and the detection method. Blood, saliva, and swabs may be used, while the device may employ an immunoassay, biosensor, or compact nucleic-acid system. Matching these choices to the intended microbial or host target supports relevant results and helps the test address clinical, infection-control, or surveillance needs.
Its main value appears when results must support a rapid decision close to the patient. In infection-related settings, testing can contribute to screening, treatment selection, infection control, and disease surveillance. Results may be available within minutes to hours, allowing these activities to proceed without relying exclusively on the timing of centralized laboratory analysis.
Depending on the assay, a result can indicate the presence of a microbial antigen, a host antibody, or nucleic-acid material. These outputs answer different questions about the infection-related sample and therefore require appropriate interpretation. Their practical value lies in connecting the detected signal with decisions about screening, treatment, infection control, or surveillance.
Ongoing development emphasizes multiplex detection and improved access in resource-limited settings. Multiplex systems could address more than one target within a testing approach, while greater accessibility could extend diagnostic support beyond settings with extensive laboratory infrastructure. Together, these directions are relevant to broader screening, infection monitoring, and disease-surveillance strategies.